

Filling your plate has never been easier.

Discover these delicious new ways to enjoy every meal!

Imagine ... taste-tempting meals that are also good for you! From everyday meal planning to special events, ADA makes your task easier with these new publications ...

Easy-to-follow nutritional guidelines you can use every day.



This new, updated version of our best-selling meal planner, *Exchange Lists for Meal Planning* brings you the latest scientific findings on good nutrition and healthful eating. Colorful charts, helpful tips on

good nutrition, and easy-to-use substitution guidelines show you how to balance your diet and gain control over diabetes.

Reprints of popular articles from *Diabetes Forecast*


A package of ten best sellers including "Think Thin," "Whiskey or Water?" and "Hamburgers to Haute Cuisine," are now available offering you timely important tips to meal planning.




Enticing new recipes for you and your family.

The American Dietetic Association Family Cookbooks (Volumes I and II)


Designed to meet the special needs of people with diabetes and their families, these comprehensive companion volumes combine to give you more than 450 imaginative,



kitchen-tested recipes available from no other source. Plus you'll find innovative nutrients-per-serving guidelines, important tips on eating out ... brown-bagging ... exercise, and more! (Individual volumes may be purchased separately.)



The American Diabetes Association Holiday Cookbook
Now you can enjoy the holidays more than ever before with these festive recipes tailored for individuals and families living with diabetes. From traditional Thanksgiving, Christmas and Hanukkah feasts ... to refreshing beverages and savory dinners for any occasion, you'll receive more than 175 tempting new recipes for appetizers, salads, soups ... even bread and cookies! And you'll regularly refer to the *newly revised* exchange equivalents, and chapters on adjusting your favorite family recipes to reduce sugar, fats, and sodium.



Start eating better today!

Yes, please send me copies of the following publications as checked (make checks payable to the American Diabetes Association):



FREE bonus copy of Healthy Food Choices with your order!

No. of Copies	Title	Total	Name
_____	<i>Exchange Lists for Meal Planning</i> , \$1.75 each	\$ _____	Address _____
_____	Packages of Ten Reprints from <i>Diabetes Forecast</i> , \$3.60 each	\$ _____	City _____
_____	<i>The American Diabetes Association/The American Dietetic Association Family Cookbook, Vol. I.</i> (a) \$17.45	\$ _____	State _____
_____	<i>The American Diabetes Association/The American Dietetic Association Family Cookbook, Vol. II.</i> (a) \$18.45	\$ _____	Zip _____
_____	<i>The American Diabetes Association Holiday Cookbook</i> , (a) \$16.45	\$ _____	Send your order to:
Total Amount Enclosed		\$ _____	The American Diabetes Association
(All prices include postage and handling)			1660 Duke Street
			Alexandria, VA 22314
			(800) ADA-DISC
			Please allow 6-8 weeks for delivery.
			Offer expires June 30, 1987.

H77901

Second Nature

sek'ənd nā'chər. *An acquired habit so deeply ingrained as to be automatic and part of a person's nature.*

Second nature comes from ease of use.

To become a second-nature tool, an object must possess certain qualities.

Simplicity. Functionality. Portability.

They are part and parcel of many tools that make our life easier and better.

Tools such as the GLUCOSCAN™ 3000 Personal Blood Glucose Meter.

Simple



Everything can be learned, but simple things are learned more easily. Almost everyone knows how to use a paper clip.

The GLUCOSCAN 3000 Meter has precisely the kind of simplicity that invites easy learning.

Like the simple procedure. The simple two-touch operation. Or the permanent factory calibration that does away with both unnecessary steps and operator errors.

The faster the learning, the easier your training job. And the greater the likelihood of continued use.

The GLUCOSCAN one-minute test and dry-blot procedure make compliance sure and simple.

And when your patients comply, you can feel confident with their treatment program.

Functional

Functional tools work small miracles every day. Using a pencil has become second nature to the degree that its brilliant, functional design is taken for granted.

The GLUCOSCAN 3000 Meter can become just such a tool for your

patients. It is packed with functional features that make testing easy and appropriate for every lifestyle.

Like the Memory Bank™ Data Log that automatically stores your patient's last 29 test readings.

Or the largest, easiest-to-read digital display in glucose monitoring. The only adjustable volume control. The longest battery life. And the longest meter warranty — three full years — included free of extra charge.

Portable

Cumbersome objects stay home. Compact ones go places. When we wear a wristwatch, we always know the time no matter where we are.

Equally, with the GLUCOSCAN 3000 Meter, your patients can test their blood sugars virtually anywhere, because the GLUCOSCAN 3000 Meter is the smallest one available.



But of what use is a small meter if all the other testing supplies are not readily at hand? The unique, truly pocket-portable GLUCOSCAN

case holds everything required for on-the-go monitoring: Individually foil-wrapped GLUCOSCAN Test Strips, PENLET™ Automatic Blood Sampling Pen, GLUCOSCAN Lancets, and, of course, the GLUCOSCAN Meter itself.

GLUCOSCAN 3000

GLUCOSCAN 3000 is more than just another meter. It's an important part of life for many people.


Some say it's second nature.

Discover how blood glucose testing can become second nature with the GLUCOSCAN 3000 Personal Blood Glucose Meter. Call us toll-free for the name of your nearest Authorized LifeScan Distributor: United States 1 800 227-8862.

Also available in the economical GLUCOSCAN 2000 model (Memory Bank not included).

LIFESCAN INC.
Mountain View, CA 94043

**Data
Manager™ unit
now available**
**call for
details**




Shown
actual size

GLUCOSCAN™ Meters

Easiest to start with.
Easiest to stay with.

Now even easier with Countdown Start



For diabetics with peripheral arterial disease...



Circulatory insufficiency—a well-known factor in the pathogenesis of diabetic complications—predisposes diabetics to intermittent claudication.¹ In addition to narrowing of the blood vessels, two specific microcirculatory abnormalities—decreased red cell flexibility and increased blood viscosity—are also associated with diabetes.^{1,2} Although ideal glucose control might correct these abnormalities, glucose levels do fluctuate, and patients remain at risk.



when microcirculatory blood flow improves, so does life.



Though glucose control may be imperfect, Trental® increases red cell flexibility and lowers blood viscosity. The flow of red cells—which are larger than the diameter of the microcirculatory vessels—is enhanced through the capillary bed, and tissue perfusion and oxygenation improve.³⁻⁵



Evidence of improved perfusion and oxygenation has been obtained from experimental measurements of partial pressures of oxygen (pO_2) in the calf muscles of patients with limb ischemia given Trental®.⁶

**Significant improvement
in stabilized diabetics?**

References: 1. Oughton J, et al. Diabetes mellitus: Its effect on the flow properties of blood. *Horm Metab Res* 11 (Suppl): 112-129, 1981. 2. Schubotz R. Double-blind trial of pentoxifylline in diabetes with peripheral vascular disorders. *Pharmatherapeutica* 1(3): 172-179, 1976. 3. Dormandy JA, et al. Clinical, hemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. *Br Med J* 4: 576, 1973. 4. Reid HL, et al. Impaired red cell deformability in peripheral vascular disease. *Lancet* 1: 666, 1967. 5. Stormer B, et al. Rheological changes in the blood of patients with chronic arterial occlusive disease after the administration of vasoactive drugs. *Curr Med Res Opin* 4: 588, 1977. 6. Ehrly AM. Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. *IRCS Med Sci* 10: 401, 1982.

Trental® (pentoxifylline) Tablets, 400 mg

A brief summary of the Prescribing Information follows.

INDICATIONS AND USAGE:

Trental® (pentoxifylline) is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Trental® (pentoxifylline) can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.

CONTRAINDICATIONS:

Trental® (pentoxifylline) should not be used in patients who have previously exhibited intolerance to this product or methylxanthines such as caffeine, theophylline, and theobromine.

PRECAUTIONS:

General: Patients with chronic occlusive arterial disease of the limbs frequently show other manifestations of arteriosclerotic disease. Trental® (pentoxifylline) has been used safely for treatment of peripheral arterial disease in patients with concurrent coronary artery and cerebrovascular diseases, but there have been occasional reports of angina, hypotension, and arrhythmia. Controlled trials do not show that Trental® (pentoxifylline) causes such adverse effects more often than placebo, but, as it is a methylxanthine derivative, it is possible some individuals will experience such responses.

Drug Interactions: Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with Trental® (pentoxifylline) with and without anticoagulants or platelet aggregation inhibitors. Patients on warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. Trental® (pentoxifylline) has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. Small decreases in blood pressure have been observed in some patients treated with Trental® (pentoxifylline); periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. If indicated, dosage of the antihypertensive agents should be reduced.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term studies of the carcinogenic potential of pentoxifylline were conducted in mice and rats by dietary administration of the drug at doses up to approximately 24 times (570 mg/kg) the maximum recommended human daily dose (MRHD) of 24 mg/kg for 18 months in mice and 18 months in rats with an additional 6 months without drug exposure in the latter. No carcinogenic potential for pentoxifylline was noted in the mouse study. In the rat study, there was a statistically significant increase in benign mammary fibroadenomas in females in the high dose group (24 X MRHD). The relevance of this finding to human use is uncertain since this was only a marginal statistically significant increase for a tumor that is common in aged rats. Pentoxifylline was devoid of mutagenic activity in various strains of *Salmonella* (Ames test) when tested in the presence and absence of metabolic activation.

Pregnancy: Category C. Teratogenic studies have been performed in rats and rabbits at oral doses up to about 25 and 10 times the maximum recommended human daily dose (MRHD) of 24 mg/kg, respectively. No evidence of fetal malformation was observed. Increased resorption was seen in rats at 25 times MRHD. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Trental® (pentoxifylline) should be used during pregnancy only if clearly needed.

Nursing Mothers: Pentoxifylline and its metabolites are excreted in human milk. Because of the potential for tumorigenicity shown for pentoxifylline in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in children below the age of 18 years have not been established.

ADVERSE REACTIONS:

Clinical trials were conducted using either controlled-release Trental® (pentoxifylline) tablets for up to 60 weeks or immediate-release Trental® (pentoxifylline) capsules for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid to tid and in the capsule studies, 200-400 mg tid.

The table summarizes the incidence (in percent) of adverse reactions considered drug related, as well as the numbers of patients who received controlled-

release Trental® (pentoxifylline) tablets, immediate-release Trental® (pentoxifylline) capsules, or the corresponding placebos. The incidence of adverse reactions was higher in the capsule studies (where dose related increases were seen in digestive and nervous system side effects) than in the tablet studies. Studies with the capsule include domestic experience, whereas studies with the controlled-release tablets were conducted outside the U.S. The table indicates that in the tablet studies few patients discontinued because of adverse effects.

INCIDENCE (%) OF SIDE EFFECTS

	Controlled-Release Tablets		Immediate-Release Capsules	
	Trental®	Placebo	Trental®	Placebo
(Numbers of Patients at Risk)	(321)	(128)	(177)	(138)
Discontinued for Side Effect	3.1	0	9.6	7.2
CARDIOVASCULAR SYSTEM				
Angina/Chest Pain	0.3	—	1.1	2.2
Arrhythmia/Palpitation	—	—	1.7	0.7
Flushing	—	—	2.3	0.7
DIGESTIVE SYSTEM				
Abdominal Discomfort	—	—	4.0	1.4
Belching/Flatus/Bloating	0.6	—	9.0	3.6
Diarrhea	—	—	3.4	2.9
Dyspepsia	2.8	4.7	9.6	2.9
Nausea	2.2	0.8	28.8	8.7
Vomiting	1.2	—	4.5	0.7
NERVOUS SYSTEM				
Agitation/Nervousness	—	—	1.7	0.7
Dizziness	1.9	3.1	11.9	4.3
Drowsiness	—	—	1.1	5.8
Headache	1.2	1.6	6.2	5.8
Insomnia	—	—	2.3	2.2
Tremor	0.3	0.8	—	—
Blurred Vision	—	—	2.3	1.4

Trental® (pentoxifylline) has been marketed in Europe and elsewhere since 1972. In addition to the above symptoms, the following have been reported spontaneously since marketing, or occurred in other clinical trials with an incidence of less than 1%; the causal relationship was uncertain: Cardiovascular—dyspnea, edema, hypotension; Digestive—anorexia, cholecystitis, constipation, dry mouth/thirst; Nervous—anxiety, confusion; Respiratory—epistaxis, flu-like symptoms, laryngitis, nasal congestion; Skin and Appendages—brittle fingernails, pruritus, rash, urticaria; Special Senses—blurred vision, conjunctivitis, ear-ache, scotoma; and Miscellaneous—bad taste, excessive salivation, leukopenia, malaise, sore throat/swollen neck glands, weight change.

A few rare events have been reported spontaneously worldwide since marketing in 1972. Although they occurred under circumstances in which a causal relationship with pentoxifylline could not be established, they are listed to serve as information for physicians: Cardiovascular—angina, arrhythmia, tachycardia; Digestive—hepatitis, jaundice; and Hemic and Lymphatic—decreased serum fibrinogen, pancytopenia, purpura, thrombocytopenia.

OVERDOSAGE:

Overdosage with Trental® (pentoxifylline) has been reported in children and adults. Symptoms appear to be dose related. A report from a poison control center on 44 patients taking overdoses of enteric-coated pentoxifylline tablets noted that symptoms usually occurred 4-5 hours after ingestion and lasted about 12 hours. The highest amount ingested was 80 mg/kg; flushing, hypotension, convulsions, somnolence, loss of consciousness, fever, and agitation occurred. All patients recovered.

In addition to symptomatic treatment and gastric lavage, special attention must be given to supporting respiration, maintaining systemic blood pressure, and controlling convulsions. Activated charcoal has been used to adsorb pentoxifylline in patients who have overdosed.

DOSAGE AND ADMINISTRATION:

The usual dosage of Trental® (pentoxifylline) in controlled-release tablet form is one tablet (400 mg) three times a day with meals.

While the effect of Trental® (pentoxifylline) may be seen within 2 to 4 weeks, it is recommended that treatment be continued for at least 8 weeks. Efficacy has been demonstrated in double-blind clinical studies of 6 months duration.

Digestive and central nervous system side effects are dose related. If patients develop these side effects it is recommended that the dosage be lowered to one tablet twice a day (800 mg/day). If side effects persist at this lower dosage, the administration of Trental® (pentoxifylline) should be discontinued.


Hoechst-Roussel Pharmaceuticals Inc.
Somerville, New Jersey 08876



A giant step toward compliance...

- Medication
- Diet
- Stopping smoking
- Exercise

Ask your Hoechst-Roussel representative for information about this innovative patient education program.



Trental® 400 mg Tablets
(pentoxifylline)

The only proven-effective agent for intermittent claudication symptomatic of peripheral arterial disease...

The name and logo HOECHST are registered trademarks of Hoechst AG.

WHEN HYPERTENSION COEXISTS WITH DIABETES...



Consider the CAPOTEN difference...

Effective control*

- 50 mg to 100 mg daily effectively controls most patients with mild hypertension¹

Fewer complications

- Studies of hypertensive patients with concurrent Type I or Type II diabetes show that CAPOTEN does not affect glucose metabolism^{2,3}
- Unlike some beta-blockers,⁴ CAPOTEN is not associated with hyperglycemic or hypoglycemic changes and does not mask the symptoms of hypoglycemia
- Unlike diuretics,⁴ CAPOTEN is not associated with impairment of glucose tolerance in diabetics

*CAPOTEN may be used as initial therapy only for patients with normal renal function in whom the risk of neutropenia/agranulocytosis is relatively low (1 out of over 8,600 in clinical trials). Use special precautions in patients with impaired renal function, collagen vascular disorders, or those exposed to other drugs known to affect the white cells or immune response. Evaluation of hypertensives should always include assessment of renal function. Overall, the most frequently occurring adverse reactions associated with CAPOTEN are skin rash and taste alteration; both effects are generally mild, reversible, or self-limited. See INDICATIONS AND USAGE, WARNINGS, and ADVERSE REACTIONS in the brief summary on adjacent page.

Novolin® is a licensed trademark of NOVO Industri A/S.

CAPOTEN[®] **LOW DOSE**
captopril tablets



CAPOTEN® TABLETS Captopril Tablets

INDICATIONS: Hypertension—CAPOTEN (captopril) is indicated for the treatment of hypertension. Consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS). CAPOTEN may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for those who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. CAPOTEN is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics.

Heart Failure: CAPOTEN (captopril) is indicated in patients with heart failure who have not responded adequately to or cannot be controlled by conventional diuretic and digitalis therapy. CAPOTEN is to be used with diuretics and digitalis.

WARNINGS: Neutropenia/Agranulocytosis—Neutropenia ($<1000/\text{mm}^3$) with myeloid hypoplasia has resulted from use of captopril. About half of the neutropenic patients developed systemic or oral cavity infections or other features of the syndrome of agranulocytosis. The risk of neutropenia is dependent on the clinical status of the patient:

In clinical trials in patients with hypertension who have normal renal function (serum creatinine <1.6 mg/dL and no collagen vascular disease), neutropenia has been seen in one patient out of over 8,600 exposed. In patients with some degree of renal failure (serum creatinine at least 1.6 mg/dL) but no collagen vascular disease, the risk in clinical trials was about 1 per 500. Doses were relatively high in these patients, particularly in view of their diminished renal function. In patients with collagen vascular diseases (e.g., systemic lupus erythematosus, scleroderma) and impaired renal function, neutropenia occurred in 3.7% of patients in clinical trials. While none of the over 750 patients in formal clinical trials of heart failure developed neutropenia, it has occurred during subsequent clinical experience. Of reported cases, about half had serum creatinine ≥ 1.6 mg/dL and more than 75% received procainamide. In heart failure, it appears that the same risk factors for neutropenia are present.

Neutropenia has appeared usually within 3 months after starting therapy, associated with myeloid hypoplasia and frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes (e.g., hypoplastic bone marrow and pancytopenia); anemia and thrombocytopenia were sometimes seen. Neutrophils generally returned to normal in about 2 weeks after captopril was discontinued, and serious infections were limited to clinically complex patients. About 13% of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors.

Evaluation of the hypertensive or heart failure patient should always include assessment of renal function. If captopril is used in patients with impaired renal function, white blood cell and differential counts should be evaluated prior to starting treatment and at approximately 2-week intervals for about 3 months, then periodically. In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is impaired renal function, captopril should be used only after an assessment of benefit and risk, and then with caution. All patients treated with captopril should be told to report any signs of infection (e.g., sore throat, fever); if infection is suspected, perform counts without delay. Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of neutropenia (neutrophil count $<1000/\text{mm}^3$) withdraw captopril and closely follow the patient's course.

Proteinuria—Total urinary proteins >1 g/day were seen in about 0.7% of patients on captopril. About 90% of affected patients had evidence of prior renal disease or received high doses (>150 mg/day), or both. The nephrotic syndrome occurred in about one-fifth of proteinuric patients. In most cases, proteinuria subsided or cleared within 6 months whether or not captopril was continued. The BUN and creatinine were seldom altered in proteinuric patients. Since most cases of proteinuria occurred by the 8th month of therapy, patients with prior renal disease or those receiving captopril at doses >150 mg/day should have urinary protein estimates (dip-stick on 1st morning urine) before therapy, and periodically thereafter.

Hypotension—Excessive hypotension was rarely seen in hypertensive patients but is a possibility in severely salt/volume-depleted persons such as those treated vigorously with diuretics (see PRECAUTIONS [Drug Interactions]).

In heart failure, where blood pressure was either normal or low, transient decreases in mean blood pressure $>20\%$ were recorded in about half of the patients. This transient hypotension may occur after any of the first several doses and is usually well tolerated, although rarely it has been associated with arrhythmia or conduction defects. A starting dose of 6.25 or 12.5 mg tid may minimize the hypotensive effect. Patients should be followed closely for the first 2 weeks of treatment and whenever the dose of captopril and/or diuretic is increased.

BECAUSE OF THE POTENTIAL FALL IN BLOOD PRESSURE IN THESE PATIENTS, THERAPY SHOULD BE STARTED UNDER VERY CLOSE MEDICAL SUPERVISION.

PRECAUTIONS: General: Impaired Renal Function, Hypertension—Some hypertensive patients with renal disease, particularly those with severe renal artery stenosis, have developed increases in BUN and serum creatinine. It may be necessary to reduce captopril dosage and/or discontinue diuretic. For some of these patients, normalization of blood pressure and maintenance of adequate renal perfusion may not be possible. **Heart Failure**—About 20% of patients develop stable elevations of BUN and serum creatinine $>20\%$ above normal or baseline upon long-term treatment. Less than 5% of patients, generally with severe preexisting renal disease, required discontinuation due to progressively increasing creatinine. See DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS [Altered Laboratory Findings]. **Valvular Stenosis**—A theoretical concern, for risk of decreased coronary perfusion, has been noted regarding vasodilator treatment in patients with aortic stenosis due to decreased afterload reduction.

Surgery/Anesthesia—If hypotension occurs during major surgery or anesthesia, and is considered due to the effects of captopril, it is correctable by volume expansion.

References: 1. Drayer JM, Weber MA: Monotherapy of essential hypertension with a converting-enzyme inhibitor. *Hypertension* 5(5-Suppl III):108-113, 1983.

2. D'Angelo A, Sartori L, Gambaro G, et al: Captopril in the treatment of hypertension in type I and type II diabetic patients. *Postgrad Med J* 62(Suppl I):69-72, 1986.

Drug Interactions: Hypotension: Patients on Diuretic Therapy—Precipitous reduction of blood pressure may occasionally occur within the 1st hour after administration of the initial captopril dose in patients on diuretics, especially those recently placed on diuretics, and those on severe dietary salt restriction or dialysis. This possibility can be minimized by either discontinuing the diuretic or increasing the salt intake about 1 week prior to initiation of captopril therapy or by initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least 1 hour after the initial dose.

Agents Having Vasodilator Activity—In heart failure patients, vasodilators should be administered with caution.

Agents Causing Renin Release—Captopril's effect will be augmented by antihypertensive agents that cause renin release.

Agents Affecting Sympathetic Activity—The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive. Therefore, use agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) with caution.

Agents Increasing Serum Potassium—Give potassium-sparing diuretics or potassium supplements only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium. Use potassium-containing salt substitutes with caution.

Inhibitors of Endogenous Prostaglandin Synthesis—Indomethacin and other nonsteroidal anti-inflammatory agents may reduce the antihypertensive effect of captopril, especially in low renin hypertension.

Drug/Laboratory Test Interaction: Captopril may cause a false-positive urine test for acetone.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Two-year studies with doses of 50 to 1350 mg/kg/day in mice and rats failed to show any evidence of carcinogenic potential. Studies in rats have revealed no impairment of fertility.

Pregnancy: Category C—There are no adequate and well-controlled studies in pregnant women. Embryocidal effects and craniofacial malformations were observed in rabbits. Therefore, captopril should be used during pregnancy, or for patients likely to become pregnant, only if the potential benefit outweighs the potential risk to the fetus. Captopril crosses the human placenta.

Nursing Mothers: Captopril is secreted in human milk. Exercise caution when administering captopril to a nursing woman, and, in general, nursing should be interrupted.

Pediatric Use: Safety and effectiveness in children have not been established although there is limited experience with use of captopril in children from 2 months to 15 years of age. Dosage, on a weight basis, was comparable to that used in adults. Captopril should be used in children only if other measures for controlling blood pressure have not been effective.

ADVERSE REACTIONS: Reported incidences are based on clinical trials involving approximately 7000 patients.

Renal—About 1 of 100 patients developed proteinuria (see WARNINGS). Renal insufficiency, renal failure, polyuria, oliguria, and urinary frequency in 1 to 2 of 1000 patients.

Hematologic—Neutropenia/agranulocytosis have occurred (see WARNINGS). Anemia, thrombocytopenia, and pancytopenia have been reported.

Dermatologic—Rash (usually maculopapular, rarely urticarial), often with pruritus and sometimes with fever and eosinophilia, in about 4 to 7 of 100 patients (depending on renal status and dose), usually during the 1st 4 weeks of therapy. Pruritus, without rash, in about 2 of 100 patients. A reversible associated pemphigoid-like lesion, and photosensitivity have also been reported. Angioedema of the face, mucous membranes of the mouth, or of the extremities in about 1 of 1000 patients—reversible on discontinuance of captopril therapy. One case of laryngeal edema reported. Flushing or pallor in 2 to 5 of 1000 patients.

Cardiovascular—Hypotension may occur, see WARNINGS and PRECAUTIONS (Drug Interactions) for discussion of hypotension on initiation of captopril therapy. Tachycardia, chest pain, and palpitations each in about 1 of 100 patients. Angina pectoris, myocardial infarction, Raynaud's syndrome, and congestive heart failure each in 2 to 3 of 1000 patients.

Dysgeusia—About 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or loss of taste perception; taste impairment is reversible and usually self-limited even with continued drug use (2 to 3 months). Gastric irritation, abdominal pain, nausea, vomiting, diarrhea, anorexia, constipation, aphthous ulcers, peptic ulcer, dizziness, headache, malaise, fatigue, insomnia, dry mouth, dyspnea, cough, alopecia, and paresthesias reported in about 0.5 to 2% of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials.

Altered Laboratory Findings: Elevations of liver enzymes in a few patients although no causal relationship has been established. Rarely cholestatic jaundice and hepatocellular injury with or without secondary cholestasis, have been reported. A transient elevation of BUN and serum creatinine may occur, especially in volume-depleted or renovascular hypertensive patients. In instances of rapid reduction of longstanding or severely elevated blood pressure, the glomerular filtration rate may decrease transiently, also resulting in transient rises in serum creatinine and BUN. Small increases in serum potassium concentration frequently occur, especially in patients with renal impairment (see PRECAUTIONS).

OVERDOSAGE: Primary concern is correction of hypotension. Volume expansion with an I.V. infusion of normal saline is the treatment of choice for restoration of blood pressure. Captopril may be removed from the general circulation by hemodialysis.

DOSAGE AND ADMINISTRATION: CAPOTEN (captopril) should be taken one hour before meals. In hypertension, CAPOTEN may be dosed bid or tid. Dosage must be individualized; see DOSAGE AND ADMINISTRATION section of package insert for detailed information regarding dosage in hypertension and in heart failure. Because CAPOTEN (captopril) is excreted primarily by the kidneys, dosage adjustments are recommended for patients with impaired renal function.

Consult package insert before prescribing CAPOTEN (captopril).

HOW SUPPLIED: Available in tablets of 12.5, 25, 50, and 100 mg in bottles of 100 (25 mg also available in bottles of 1000), and in UNIMATIC® single dose packs of 100 tablets. (J3-658D)

3. Matthews DM, Wathen CG, Bell D, et al: The effect of captopril on blood pressure and glucose tolerance in hypertensive non-insulin dependent diabetics. *Postgrad Med J* 62(Suppl I):73-75, 1986.

4. Christlieb AR: Management of hypertension in the patient with diabetes mellitus. *Practical Cardiol* 8:94-103, 1982.

DIABETES

HEART DISEASE, KIDNEY DISEASE, AND BLINDNESS HAVE A COMMON WARNING SIGN.

Diabetes is a major contributor to heart disease, kidney disease and blindness. Physicians believe, however, that early detection of diabetes can help reduce or minimize severe complications later on.

Some of diabetes' most obvious warning

signs are frequent urination, unusual hunger, excessive thirst, rapid weight loss, blurred vision, skin infections and slow healing.

If you have any of the above symptoms, take a warning from us.

See your physician.

FIGHT SOME OF THE WORST DISEASES OF OUR TIME.
Support the American Diabetes Association. 

The Future of Human Insulin Delivery Is Here

The first comprehensive, streamlined human insulin delivery system



Designed for the lifestyle of your patients with diabetes

Convenient:

- Sleek fountain-pen design makes it lightweight and portable.
- Eliminates the need for conventional syringes and vials for Novolin® R Human Insulin (semi-synthetic).

Discreet:

- Unobtrusive carrying and handling of NovoPen® may encourage adherence to multiple daily injection regimens.
- Easy to administer insulin away from home.

Accurate:

- Push-button measurement designed for accurate delivery of two or more units of Novolin® R Insulin.
- Eliminates dosing errors that may result from visually estimating dose.

For further information about NovoPen®, call 1-800-334-3678. In New Jersey, call 1-800-367-0249.

NovoPen® bringing new simplicity and convenience to life with diabetes.

